Ubiquitin‑like modifier‑activating enzyme 7 as a marker for the diagnosis and prognosis of breast cancer

Lin,Meng; Li,Yanqing; Qin,Shanshan; Jiao,Yan; Hua,Fang

doi:10.3892/ol.2020.11406

Ubiquitin‑like modifier‑activating enzyme 7 as a marker for the diagnosis and prognosis of breast cancer

Authors:
- Meng Lin
- Yanqing Li
- Shanshan Qin
- Yan Jiao
- Fang Hua
View Affiliations

Affiliations: Department of Breast Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Pathophysiology, College of Basic Medical Science, Jilin University, Changchun, Jilin 130021, P.R. China, Department of Radiology, Affiliated Hospital of Qingdao University, Qingdao, Shandong 266000, P.R. China, Department of Hepatobiliary and Pancreatic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Cardiovascular Center, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: February 17, 2020 https://doi.org/10.3892/ol.2020.11406
Pages: 2773-2784
Copyright: © Lin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ubiquitin‑like modifier‑activating enzyme 7 (UBA7) is a specific E1‑like ubiquitin‑activating enzyme involved in interferon‑stimulated gene 15 (ISG15) conjugation. UBA7 expression has been reported to be notably decreased in lung cancer. The present study aimed to investigate the changes in UBA7 expression in breast cancer and the association between UBA7 expression and clinical characteristics, and to elucidate the diagnostic and prognostic significance of UBA7 in breast cancer. The clinical data and RNA‑sequencing expression values of 1,104 patients with breast cancer were downloaded from The Cancer Genome Atlas database. The associations between UBA7 expression and clinical characteristics were determined using χ2 and Fisher's exact tests. UBA7 expression values were divided into low and high groups using the optimal cut‑off value, as determined by the overall survival (OS) value identified via a receiver operating characteristic (ROC) curve analysis, to further study the association between UBA7 expression and clinical characteristics. The diagnostic capability of UBA7 was assessed via ROC analysis, and Kaplan‑Meier curve and Cox regression analyses were performed to determine the prognostic value of UBA7. The results demonstrated that UBA7 expression was decreased in breast cancer, and significant differences were observed between groups with regards to vital status, tumor classification, metastasis classification, histological type, sex, molecular subtype, and expression levels of progesterone receptor, estrogen receptor (ER) and human epidermal growth factor receptor 2. Low and high UBA7 expression levels were associated with age, ER expression, menopause status, Tumor‑Node‑Metastasis classification stage, margin status, vital status, radiation therapy use, OS and relapse‑free survival. Furthermore, patients with low UBA7 expression levels had a poor prognosis. UBA7 expression also demonstrated an ability to diagnose patients at all clinical stages. Taken together, the results indicated that UBA7 expression was significantly decreased in breast cancer, and was associated with clinical characteristics and prognosis. Thus, UBA7 can be deemed as a potential biomarker in breast cancer, and may serve as a target in treatment.

View Figures

View References

1	Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ and Cronin KA: Lifetime risk (Percent) of dying from cancer by site and race/ethnicity: Female, Total U.S., 2014–2016. SEER Cancer Statistics Review. 1975-2016, National Cancer Institute; Bethesda, MD, USA:
2	American Cancer Society, . Breast Cancer Facts & Figures 2017–2018. American Cancer Society, Inc.; Atlanta, GA: 2017
3	Zhang X, Bogunovic D, Payelle-Brogard B, Francois-Newton V, Speer SD, Yuan C, Volpi S, Li Z, Sanal O, Mansouri D, et al: Human intracellular ISG15 prevents interferon-α/β over-amplification and auto-inflammation. Nature. 517:89–93. 2015. View Article : Google Scholar : PubMed/NCBI
4	Jeon YJ, Yoo HM and Chung CH: ISG15 and immune diseases. Biochim Biophys Acta. 1802:485–496. 2010. View Article : Google Scholar : PubMed/NCBI
5	Zhou MJ, Chen FZ, Chen HC, Wan XX, Zhou X, Fang Q and Zhang DZ: ISG15 inhibits cancer cell growth and promotes apoptosis. Int J Mol Med. 39:446–452. 2017. View Article : Google Scholar : PubMed/NCBI
6	Zhao C, Denison C, Huibregtse JM, Gygi S and Krug RM: Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci USA. 102:10200–10205. 2005. View Article : Google Scholar : PubMed/NCBI
7	Darb-Esfahani S, Sinn BV, Rudl M, Sehouli J, Braicu I, Dietel M and Denkert C: Interferon-stimulated gene, 15 kDa (ISG15) in ovarian high-grade serous carcinoma: Prognostic impact and link to NF-κB pathway. Int J Gynecol Pathol. 33:16–22. 2014. View Article : Google Scholar : PubMed/NCBI
8	Yin X, Cong X, Yan M and Zhang DE: Deficiency of a potential 3p21.3 tumor suppressor gene UBE1L (UBA7) does not accelerate lung cancer development in K-rasLA2 mice. Lung Cancer. 63:194–200. 2009. View Article : Google Scholar : PubMed/NCBI
9	Feng Q, Sekula D, Guo Y, Liu X, Black CC, Galimberti F, Shah SJ, Sempere LF, Memoli V, Andersen JB, et al: UBE1L causes lung cancer growth suppression by targeting cyclin D1. Mol Cancer Ther. 7:3780–3788. 2008. View Article : Google Scholar : PubMed/NCBI
10	Jiang A, Li Y, Wang P, Shan X, Jiang P, Wang X and Feng Q: Mechanism of dose-dependent regulation of UBE1L by polyphenols in human bronchial epithelial cells. J Cell Biochem. 116:1553–1562. 2015. View Article : Google Scholar : PubMed/NCBI
11	Pitha-Rowe I, Petty WJ, Feng Q, Koza-Taylor PH, Dimattia DA, Pinder L, Dragnev KH, Memoli N, Memoli V, Turi T, et al: Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Res. 64:8109–8115. 2004. View Article : Google Scholar : PubMed/NCBI
12	Jiang AP, Zhou DH, Meng XL, Zhang AP, Zhang C, Li XT and Feng Q: Down-regulation of epidermal growth factor receptor by curcumin-induced UBE1L in human bronchial epithelial cells. J Nutr Biochem. 25:241–249. 2014. View Article : Google Scholar : PubMed/NCBI
13	Samur MK: RTCGAToolbox: A new tool for exporting TCGA Firehose data. PLoS One. 9:e1063972014. View Article : Google Scholar : PubMed/NCBI
14	R Core Team: A language and environment for statistical computing. R Foundation for Statistical Computing; Vienna, Austria: 2012, Available online at. https://www.R-project.org/
15	Jiao Y, Fu Z, Li Y, Meng L and Liu Y: High EIF2B5 mRNA expression and its prognostic significance in liver cancer: A study based on the TCGA and GEO database. Cancer Manag Res. 10:6003–6014. 2018. View Article : Google Scholar : PubMed/NCBI
16	Jiao Y, Li Y, Lu Z and Liu Y: High trophinin-associated protein expression is an independent predictor of poor survival in liver cancer. Dig Dis Sci. 64:137–143. 2019. View Article : Google Scholar : PubMed/NCBI
17	Jiao Y, Fu Z, Li Y, Zhang W and Liu Y: Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer. PLoS One. 14:e02112912019. View Article : Google Scholar : PubMed/NCBI
18	Jiao Y, Li Y, Jiang P, Han W and Liu Y: PGM5: A novel diagnostic and prognostic biomarker for liver cancer. PeerJ. 7:e70702019. View Article : Google Scholar : PubMed/NCBI
19	Jiao Y, Li Y, Liu S, Chen Q and Liu Y: ITGA3 serves as a diagnostic and prognostic biomarker for pancreatic cancer. Onco Targets Ther. 12:4141–4152. 2019. View Article : Google Scholar : PubMed/NCBI
20	Hou L, Zhang X, Jiao Y, Li Y, Zhao Y, Guan Y and Liu Z: ATP binding cassette subfamily B member 9 (ABCB9) is a prognostic indicator of overall survival in ovarian cancer. Medicine (Baltimore). 98:e156982019. View Article : Google Scholar : PubMed/NCBI
21	Sun Z, Sun L, He M, Pang Y, Yang Z and Wang J: Low BCL7A expression predicts poor prognosis in ovarian cancer. J Ovarian Res. 12:412019. View Article : Google Scholar : PubMed/NCBI
22	Li Y, Jiao Y, Fu Z, Luo Z, Su J and Li Y: High miR-454-3p expression predicts poor prognosis in hepatocellular carcinoma. Cancer Manag Res. 11:2795–2802. 2019. View Article : Google Scholar : PubMed/NCBI
23	Cai H, Jiao Y, Li Y, Yang Z, He M and Liu Y: Low CYP24A1 mRNA expression and its role in prognosis of breast cancer. Sci Rep. 9:137142019. View Article : Google Scholar : PubMed/NCBI
24	Cui Y, Jiao Y, Wang K, He M and Yang Z: A new prognostic factor of breast cancer: High carboxyl ester lipase expression related to poor survival. Cancer Genet. 239:54–61. 2019. View Article : Google Scholar : PubMed/NCBI
25	Kok K, Hofstra R, Pilz A, van den Berg A, Terpstra P, Buys CH and Carritt B: A gene in the chromosomal region 3p21 with greatly reduced expression in lung cancer is similar to the gene for ubiquitin-activating enzyme. Proc Natl Acad Sci USA. 90:6071–6075. 1993. View Article : Google Scholar : PubMed/NCBI
26	McLaughlin PM, Helfrich W, Kok K, Mulder M, Hu SW, Brinker MG, Ruiters MH, de Leij LF and Buys CH: The ubiquitin-activating enzyme E1-like protein in lung cancer cell lines. Int J Cancer. 85:871–876. 2000. View Article : Google Scholar : PubMed/NCBI
27	Kok K, Van den Berg A, Veldhuis PM, Franke M, Terpstra P and Buys CH: The genomic structure of the human UBE1L gene. Gene Expr. 4:163–175. 1995.PubMed/NCBI
28	Borsini A, Cattaneo A, Malpighi C, Thuret S, Harrison NA; MRC ImmunoPsychiatry Consortium, ; Zunszain PA and Pariante CM: Interferon-alpha reduces human hippocampal neurogenesis and increases apoptosis via activation of distinct STAT1-dependent mechanisms. Int J Neuropsychopharmacol. 21:187–200. 2018. View Article : Google Scholar : PubMed/NCBI
29	Kitareewan S, Pitha-Rowe I, Sekula D, Lowrey CH, Nemeth MJ, Golub TR, Freemantle SJ and Dmitrovsky E: UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia. Proc Natl Acad Sci USA. 99:3806–3811. 2002. View Article : Google Scholar : PubMed/NCBI
30	Carpi A, Nicolini A, Antonelli A, Ferrari P and Rossi G: Cytokines in the management of high risk or advanced breast cancer: An update and expectation. Curr Cancer Drug Targets. 9:888–903. 2009. View Article : Google Scholar : PubMed/NCBI
31	Ren WB, Xia XJ, Huang J, Guo WF, Che YY, Huang TH and Lei LC: Interferon-γ regulates cell malignant growth via the c-Abl/HDAC2 signaling pathway in mammary epithelial cells. J Zhejiang Univ Sci B. 20:39–48. 2019. View Article : Google Scholar : PubMed/NCBI